2,756 reports of this reaction
24.7% of all BRIMONIDINE reports
#1 most reported adverse reaction
TREATMENT FAILURE is the #1 most commonly reported adverse reaction for BRIMONIDINE, manufactured by Padagis Israel Pharmaceuticals Ltd. There are 2,756 FDA adverse event reports linking BRIMONIDINE to TREATMENT FAILURE. This represents approximately 24.7% of all 11,162 adverse event reports for this drug.
Patients taking BRIMONIDINE who experience treatment failure should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
TREATMENT FAILURE is a frequently reported adverse event for BRIMONIDINE, accounting for a significant proportion of all reports.
In addition to treatment failure, the following adverse reactions have been reported for BRIMONIDINE:
The following drugs have also been linked to treatment failure in FDA adverse event reports:
TREATMENT FAILURE has been reported as an adverse event in 2,756 FDA reports for BRIMONIDINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
TREATMENT FAILURE accounts for approximately 24.7% of all adverse event reports for BRIMONIDINE, making it one of the most commonly reported side effect.
If you experience treatment failure while taking BRIMONIDINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.